Acute Respiratory Distress Syndrome News and Research RSS Feed - Acute Respiratory Distress Syndrome News and Research

Lifestyle choices more likely to influence quality of life for ARDS survivors

Lifestyle choices more likely to influence quality of life for ARDS survivors

A new study of patients who survive the once-nearly fatal Acute Respiratory Distress Syndrome (ARDS) finds their subsequent quality of life has more to do with lifestyle factors than how sick they were in the hospital. [More]
Scientists detect gut bacteria in deepest reaches of failing lungs

Scientists detect gut bacteria in deepest reaches of failing lungs

No one knows for sure how they got there. But the discovery that bacteria that normally live in the gut can be detected in the lungs of critically ill people and animals could mean a lot for intensive care patients. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
New set of practice guidelines from WMS may help in treatment, prevention of drowning

New set of practice guidelines from WMS may help in treatment, prevention of drowning

Drowning is a global threat to human health. Each year, more than 372,000 people die as a result of drowning, with many of those deaths being preventable by simple water safety measures. In order to arm professionals with the most up-to-date clinical protocols, the Wilderness Medical Society has issued a new set of practice guidelines for both the treatment and prevention of drowning, published in the society's official journal, Wilderness and Environmental Medicine. [More]
Researchers investigate effects of new steroid treatment on children with ARDS

Researchers investigate effects of new steroid treatment on children with ARDS

Acute Respiratory Distress Syndrome (ARDS) affects hundreds of thousands of people each year, many of them children. Those with this life threatening condition have severely injured and wet lungs, and are treated with mechanical ventilation. [More]
Patients who survived life-threatening illness in ICU at increased risk for psychiatric symptoms

Patients who survived life-threatening illness in ICU at increased risk for psychiatric symptoms

Results of a multi-institutional national study of nearly 700 people who survived life-threatening illness with a stay in an intensive care unit (ICU) suggest that a substantial majority of them are at high risk for persistent depression, anxiety and post-traumatic stress disorder — especially if they are female, young and unemployed. [More]
Scientists develop new drug for life-threatening lung disease treatment

Scientists develop new drug for life-threatening lung disease treatment

Researchers are developing a new drug to treat life-threatening lung damage and breathing problems in people with severe infections like pneumonia, those undergoing certain cancer treatments and premature infants with underdeveloped, injury prone lungs. [More]
Seasonal trivalent influenza vaccination during pregnancy may guard against stillbirth

Seasonal trivalent influenza vaccination during pregnancy may guard against stillbirth

Seasonal influenza vaccination may guard against stillbirth, a new study published in Clinical Infectious Diseases and available online suggests. Researchers in Western Australia analyzed data from nearly 60,000 births that occurred during the southern hemisphere's 2012 and 2013 seasonal influenza epidemics, and found that women who received the trivalent influenza vaccine during pregnancy were 51 percent less likely to experience a stillbirth than unvaccinated mothers. [More]
Variations in Tie2 gene play significant role in patient responses to infections

Variations in Tie2 gene play significant role in patient responses to infections

Major infections such as influenza and bacterial sepsis kill millions of people each year, often resulting fro dangerous complications that impair the body's blood vessels. But the reasons why some patients experience these dramatic responses to infections -- and others don't -- have been unclear. [More]
Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients who are exposed to higher daily levels of ozone are more likely to develop acute respiratory disease syndrome (ARDS), according to a new study published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
CareFusion to display new respiratory solutions at AARC Congress

CareFusion to display new respiratory solutions at AARC Congress

CareFusion, a BD company, will be displaying new respiratory solutions that are designed to put patients first, whether ventilated or breathing on their own, at the American Association for Respiratory Care Congress being held Nov. 7-10 in Tampa, Fla. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Potential new treatment for sepsis and ARDS

Potential new treatment for sepsis and ARDS

Scientists at Queen's University Belfast are developing a potential revolutionary new treatment for Sepsis and Acute Respiratory Distress Syndrome (ARDS), which are among the leading causes of death in hospitalised patients in the UK. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

McMaster University research, published online today by the Annals of Internal Medicine, has demonstrated the benefits of corticosteroid therapy for one of the most common serious medical conditions. [More]
ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital. [More]
The Lancet publishes new Seminar on MERS

The Lancet publishes new Seminar on MERS

Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security. [More]
ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® [More]
ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Advertisement
Advertisement